Pular para o conteúdo principalPular para a barra de ferramentas
Sobre o WordPress
Interfarma
00 comentário esperando moderação
Novo
Ver página
EnglishFiltra conteúdo por idiomaEnglish
Purge SG Cache
Olá, Interfarma
Área Restrita
Sair
Opções de telaAjuda
Editar página Adicionar nova
Adicionar título
Code of Conduct
Link permanente: https://staging.interfarma.org.br/en/Slug do URL
code-of-conduct
/ OK Cancelar
Mover para cimaMover para baixoAlternar painel: Page Compliance
Código
Treinamento
Penalidade
Perguntas e Respostas
Casos Julgados
IFPMA
Conselheiros
Conselheiros Internos
Título
Training
Descrição
Adicionar mídiaVisualTexto
The objective of the training is to present the 2021 revision of Interfarma’s Code of Conduct to Associates, Adherents and other stakeholders and reinforce the commitments and ethical principles that guide the relations of the Research Pharmaceutical Industry with its publics, focusing on innovation and discovery of health products, always observing the legality and ethical, moral and technical standards recognized locally and internationally.
Click here to access the training
Mover para cimaMover para baixoAlternar painel: Idiomas
Idioma
Idioma
English
English
Traduções
Português Editar a tradução em Português Tradução
Código de Conduta
Mover para cimaMover para baixoAlternar painel: Publicar
Visualizar alterações(abrir em uma nova aba)
Status: Publicado EditarEditar status
Visibilidade: Público EditarEditar visibilidade
Publicado em: 21 de maio de 2023 às 20:54 EditarEditar data e hora
Mover para lixeira
Mover para cimaMover para baixoAlternar painel: Atributos da página
Ascendente
(sem ascendente)
Modelo
Condute
Ordem
0
Precisa de ajuda? Utilize a aba Ajuda acima do título da tela.
Mover para cimaMover para baixoAlternar painel: Imagem destacada
Definir imagem destacada
Mover para cimaMover para baixoAlternar painel: Comentários
Obrigado por criar com WordPress.Versão 6.2.2
In 2019, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) adopted the new ETHOS, a new approach that envisions the Pharmaceutical Industry’s commitments to integrity, values and ethical principles , and serves as a guide for any interactions with the scientific community and with patients. Check out the content on the Links:
IFPMA Code of 2 019 – English
IFPMA Code of Practice – Japanese a>
IFPMA Code of Practice – Spanish a>
IFPMA Code of Practice – French a>
IFPMA Code of Practice – Portuguese
IFPMA Code of Practice 2019 – IFPMA Ethos
INTERFARMA shares these values and principles, already aligned in its Code of Conduct.

A primeira versão do Código de Conduta foi lançada em 2007 com o objetivo de formalizar a relação entre a
indústria farmacêutica e os profissionais da saúde, fazendo da INTERFARMA a entidade precursora do setor
farmacêutico a ter um Código de Conduta. Em 2012, em função de um acordo inédito, o documento se tornou o
primeiro a ser validado pelo Conselho Federal de Medicina (CFM), Associação Médica Brasileira (AMB) e
Sociedade Brasileira de Cardiologia. Veja aqui o posicionamento assinado entre as entidades. Atualmente, a
INTERFARMA é a única associação que possui um Conselho de Ética independente, Corregedoria e a esfera de
Conciliação.
A primeira versão do Código de Conduta foi lançada em 2007 com o objetivo de formalizar a relação entre a
indústria farmacêutica e os profissionais da saúde, fazendo da INTERFARMA a entidade precursora do setor
farmacêutico a ter um Código de Conduta. Em 2012, em função de um acordo inédito, o documento se tornou o
primeiro a ser validado pelo Conselho Federal de Medicina (CFM), Associação Médica Brasileira (AMB) e
Sociedade Brasileira de Cardiologia. Veja aqui o posicionamento assinado entre as entidades. Atualmente, a
INTERFARMA é a única associação que possui um Conselho de Ética independente, Corregedoria e a esfera de
Conciliação.
Interfarma’s Code of Conduct determines that the Board of Ethics is the collegiate body responsible for judging complaints submitted to INTERFARMA related to violations of our Code of Conduct. The Board of Ethics of our Association has an ad hoc character and is composed of internally drawn counselors (members of Interfarma Associates) and external professionals appointed by the Association. Get to know the professionals that make up Interfarma’s External Board of Directors:
Terezinha de Jesus Andreoli Pinto +
Pharmacist-Biochemistry, Master and PhD from the Faculty of Pharmaceutical Sciences-USP. She was head of the Department of Pharmacy, Deputy Director and Director of the Faculty of Pharmacy in two terms. She was president of the FURP Deliberative Council. She coordinated FCF’s Environmental Management Project and USP’s participation in the Drug Advertising Monitoring Project with ANVISA. She was Coordinator of TCC of the Brazilian Pharmacopoeia, Stakeholder of the US Pharmacopeia, Coordinator of CONFAR and President Director of the Instituto Pesquisas Farmacêuticas Foundation (FIPPARMA). Among other honors, she received the IPS Medal Award from the International Pharmaceutical Federation (FIP) in Basel; in Brasilia, the Commendation of Pharmaceutical Merit from the Federal Council of Pharmacy. She was patron of FCF graduates. She is a member of the Brazilian Academy of Pharmaceutical Sciences, a Brazilian reference in the pharmaceutical field. It maintains intense academic activity, with research projects and partnerships at national and international level.
http://lattes.cnpq.br/8115987312003585
Michel Durand Mura +
Michel Durand Mura is currently Managing Partner and main shareholder of MURAM Assessoria Empresarial Ltda, a consulting company focused on business development and M&A activities in the pharmaceutical area in Latin America. He is a permanent member of the Board of Directors of the CCFB (France-Brazil Chamber of Commerce) and former president of the same organization (2005-2009) and of Eurocamaras (2006-2007). He was a founding member of Interfarma as a representative of the European Group.
French and Mexican by naturalization, he graduated in 1968 with an MBA from HEC (École des Hautes Études Commerciales). From 1969 to 1974, he served as Assistant to the Director of Human Resources at the Canadian Ministry of Transport in Quebec (1969-70). Between 1970 and 1972, in Mexico, he was Commercial Director of Vitaminas y Minerales Complementarios S.A (animal nutrition), and General Manager and main shareholder of Start Computación SA (informatics), also in Mexico, between 1972 and 1974.
In 1974, while still in Mexico, he joined the Hoechst Group as Administrative and Financial Director of the Roussel Group. In 1976, he became Deputy General Manager and, from 1980 to 1982, General Manager. From 1983 to 1992, he was simultaneously President of two Brazilian companies of the Roussel Group: SARSA – Laboratório Silva Araújo Roussel S.A. and Chemo – Chemical Products Com. Ind. S.A., both in Rio de Janeirol. From 1989, he also accumulated responsibilities in the pharmaceutical and agricultural divisions as Vice President of Hoechst do Brasil. In 1992, Michel Durand Mura was appointed General Manager for Latin America at Groupe Roussel Uclaf. From July 1994 to July 1995, he was President of Hoechst do Brasil. After the formation of Hoechst Marion Roussel, a pharmaceutical company of the Hoechst Group, he was appointed President for Latin America and member of the Executive Committee, a position he held from July 1995 to December 1999.
Aventis, the result of the merger between Hoechst and Rhône Poulenc, confirmed Michel Durand Mura as President in Latin America and member of OPCOM (Operations Committee), a position he held until May 31, 2005, when he retired, after a transition from year as Regional President of the newly created Sanofi-Aventis Group.
In 2007, Michel Durand Mura was named a Chevalier of the French Legion of Honor.
Hader Armando José +
Born in São Paulo, age 64, lawyer registered with the OAB/SP under n. 75,318, employee of the Brazilian unit of the Boehringer Ingelheim group for 40 years, having initially acted as responsible for organizing documents for bids and later for the Tax and Legal areas and, interim, DRH.
As responsible for the Legal area, I had the opportunity to experience important facts that changed the course of the pharmaceutical sector in Brazil, such as the creation of ANVISA and CMED, CPI on Medicines, patent legislation, among others.
I participated in the creation of Interfarma’s Code of Conduct, under the coordination of my colleague Ronaldo Pires, as well as the current Department of Compliance and Ethics at Boehringer.
Dr. Joaquim Prado Pinto de Moraes-Filho +
He is a Doctor in Medicine and Full Professor at the Faculty of Medicine of the University of São Paulo, USP. He was Director of Communication (2021-2022) at the Brazilian Federation of Gastroenterology, FBG; member of the American College of Physicians and the American College of Gastroenterology. He has 150 works published in Brazil and abroad. Author of six books on Medicine/Gastroenterology. He was also Medical Director at Merck Sharp & Dohme and Executive Medical Director, also at MSD. He also sees patients in a private clinic.
Dr. Eduardo Najjar Roque +
Eduardo Najjar Roque graduated in Law in 1977.
He has several courses, including the Pfizer Leadership Development Program, held at Harvard University.
He has over 35 years of experience working as a lawyer at Pfizer-Brasil (Laboratório Pfizer Ltda), where he held positions as Director of Legal and Corporate Affairs.
He actively participated in the acquisition and integration processes of Parke-Davis / Warner-Lambert, Pharmacia and Wyeth.
He was a member of INTERFARMA’s Audit Committee and is currently a member of the Ethics Committee of said entity.
Currently, he provides business consulting services, as well as takes care of family businesses in the management of assets.
Dr. Ernesto Neumann
Alexandre Dalmasso +
Alex Dalmasso is one of the most renowned compliance professionals in Brazil, working in legal and compliance departments of large multinational companies for the last 27 years, leading them for the last 22 years and leading Compliance departments for the last 14 years. In addition to his solid academic background at renowned colleges in Brazil, his educational highlights include two MBAs in Business Law and Audit and Controls, Policy and Strategy from the Higher Graduate Association of the Escola de Guerra and Compliance Certification from Seton Hall University.
His legal milestones include two mergers, production outsourcing agreements, the sale of two factories, the negotiation of 21 products, as well as a wide range of licensing and distribution agreements. In the compliance area, a direct participation in the implementation of a robust compliance program resulting from a conduct adjustment term and a consent decree in the USA, the elaboration of a compliance manual for emerging markets and the creation of guidelines to classify third parties and carry out the corresponding due diligences, globally.
Alex regularly participates in various national and international compliance congresses and is up-to-date with the latest compliance trends around the world. Alex is a leading compliance thought leader.
Alex is fluent in Portuguese, English, Spanish, French and Italian. He also has notions of Japanese, German and Russian.
Alex has dual nationality: Brazilian and Italian.
Alex was elected as one of the 20 most admired compliance directors in Brazil by the LEC in Dec / 2018.
Devaney Baccarin +
Devaney Baccarin is a pharmacist-biochemist graduated from USP, a journalist from Fundação Cásper Líbero and has an MBA in strategic management from ITA-ESPM.
He worked for 38 years in the pharmaceutical industry, starting his career in technical areas such as quality assurance and production, rising successively to sales force, market research and productivity, human resources, marketing, corporate affairs and presidencies.
Companies where he has been a senior manager and director include Merrell Lepetit, Schering, Roche, Wyeth and Eli Lilly.
He was president of four companies: Whitehall (Wyeth Consumer), Genzyme, Astellas and Recordati Rare Diseases, with the latter two responsible for starting operations in Brazil.
After three decades as an industry executive, he established his own consultancy, Baccarind Assessoria Empresarial, where he worked with clients on M&A projects, regulatory affairs and logistics optimization.
Devaney had an associative role in the various entities of the pharmaceutical industry, having held the presidency of ABIMIP, and member of the boards of Sindusfarma, Febrafarma and three terms as head of the board of Interfarma. He was the first president of Interfarma’s access commission, a successful commission in a series of claims that resulted in the creation of CONITEC.
He holds a chair as an academician of the Brazilian Academy of Pharmaceutical Sciences – National Academy of Pharmacy.
Devaney is currently a partner at Odgers Berndtson Executive Search for the areas of life science & healthcare.
Paulo Tadeu de Oliveira Dorta +
Born in São Paulo in 1964. At the end of 1983, I joined the Boehringer Ingelheim pharmaceutical company in Brazil, as an assistant in the legal department, responsible for obtaining and maintaining documents for the company’s qualification in bidding procedures. In 1989 I graduated in Law and Social Sciences from FMU – Faculdades Metropolitanas Unidas, registered with the OAB/SP under number 107.743 in 1990. In 1996 I took a specialization course in Business Law at Universidade Mackenzie. In 2003 I took a specialization course in Labor Law and Labor Procedural Law – Mascaro and Mannrich Center for Cultural Development. I remained at Boehringer Ingelheim do Brasil until 01.01.2019, always working in the legal area, having held several positions, the last of which, from September 2014, as Senior Compliance Manager – Compliance Officer, when I had the opportunity to be the responsible for the local implementation of the Company’s Global Compliance Program, including participation in Commissions with Interfarma, as Compliance Commission and also in its Ethics Council, as Internal Counselor.
Marcos Lobo de Freitas Levy +
Marcos Lobo de Freitas Levy graduated in Law from the University of São Paulo in 1977 and has more than 40 years of experience working as an in-house lawyer for large companies and as an external consultant. He is the author of several articles, published in various media, on pharmaceutical regulatory, business ethics, and intellectual property. The articles are also published on the blog www.MarcosLevy.blogspot.com.br
He was Legal and Corporate Affairs Director at MSD (Merck Sharp & Dohme), Legal Director and “Associate General Cousel” at Pharmacia Brasil and Institutional Relations Director at Boehringer Ingelheim.
He is a member of the Latin American Association of Ethics in Business and Economics, being Vice President of the Association from 2002 to 2003 and President from 2003 to 2005.
His work in the Life Sciences area has been recognized by the publications: “Who is Who Legal”, “Chambers & Partners Expert Guides”, “Global Health & Pharma”, “Leaders League” and “Best Lawyers in Brazil”®.
He is co-author of the “International Comparative Legal Guide on Pharmaceutical Advertising” (from 2015 to 2020) and of the Brazilian chapter of the “Global Chambers Practice Guide in Life Sciences”, published in 2018. He is also co-author of the “Chambers Global Practice Guides – Pharmaceutical Advertising” published in 2021 and 2022.